Cybin announces poster presentations at the 2024 american college of neuropsychopharmacology annual meeting, including cyb003 12-month efficacy results

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the presentation of two posters at the american college of neuropsychopharmacology (“acnp”) annual meeting taking place december 8-11, 2024, in phoenix, arizona. the data presented include 12-month efficacy result.
CYBN Ratings Summary
CYBN Quant Ranking